What do we know about the drug industry’s agenda to quiet the drumbeat of cost control and transparency proposals? How will the industry target its efforts? Will the battles take place at the state level? KHN senior correspondent Jay Hancock discussed these issues on Facebook Live Wednesday.
For more in-depth conversations with KHN reporters, check out our .
- Share on X (Opens in new window) X
- Share on Facebook (Opens in new window) Facebook
- Share on LinkedIn (Opens in new window) LinkedIn
- Email a link to a friend (Opens in new window) Email
- Print (Opens in new window) Print
- Republish This Story
Ñî¹óåú´«Ã½Ò•îl Health News' coverage of prescription drug development, costs and pricing is supported in part by the .
Ñî¹óåú´«Ã½Ò•îl Health News is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF—an independent source of health policy research, polling, and journalism. Learn more about .Some elements may be removed from this article due to republishing restrictions. If you have questions about available photos or other content, please contact NewsWeb@kff.org.
